These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7684214)

  • 1. Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits.
    Emori M; Saito H; Sato K; Tomioka H; Setogawa T; Hidaka T
    Antimicrob Agents Chemother; 1993 Apr; 37(4):722-8. PubMed ID: 7684214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice.
    Tomioka H; Saito H; Sato K; Yamane T; Yamashita K; Hosoe K; Fujii K; Hidaka T
    Antimicrob Agents Chemother; 1992 Feb; 36(2):387-93. PubMed ID: 1605603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols].
    Tomioka H; Saito H
    Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, in Mycobacterium intracellulare infection induced in mice].
    Saito H; Tomioka H; Sato K; Hidaka T
    Kekkaku; 1994 Feb; 69(2):59-63. PubMed ID: 8126989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, administered at the different periods of infection in Mycobacterium intracellulare--infected mice].
    Tomioka H; Sato K; Saito H; Hidaka T
    Kekkaku; 1993 Oct; 68(10):631-5. PubMed ID: 8255070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice].
    Akaki T; Sato K; Shimizu T; Tomioka H; Kawahara S
    Kekkaku; 1997 Aug; 72(8):491-7. PubMed ID: 9293712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of in vivo therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, in SCID mouse model for disseminated Mycobacterium avium complex infection.
    Emori M; Tomioka H; Sato K; Saito H
    Int J Antimicrob Agents; 1998 Apr; 10(1):59-65. PubMed ID: 9624545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of half-sized secretory leukocyte protease inhibitor and Chinese traditional medicines, yokuinin and mao-bushi-saishin-to, on therapeutic efficacies of benzoxazinorifamycin KRM-1648 against Mycobacterium avium complex infection induced in mice].
    Sato K; Shimizu T; Tomioka H; Kawahara S
    Kekkaku; 1998 Aug; 73(8):501-6. PubMed ID: 9780605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection.
    Bermudez LE; Kolonoski P; Young LS; Inderlied CB
    Antimicrob Agents Chemother; 1994 Aug; 38(8):1844-8. PubMed ID: 7986018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis: (1). A study on the efficacy of short course treatment with the intratracheal and intravenous infection model].
    Doi N
    Kekkaku; 1998 Feb; 73(2):53-64. PubMed ID: 9545697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, administered in various frequencies per week in Mycobacterium intracellulare-infected mice].
    Tomioka H; Sato K; Saito H; Dekio S; Hidaka T
    Kekkaku; 1993 Nov; 68(11):683-6. PubMed ID: 8264123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice?
    Ji B; Lounis N; Truffot-Pernot C; Grosset J
    Antimicrob Agents Chemother; 1996 Feb; 40(2):437-42. PubMed ID: 8834894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice.
    Reddy MV; Luna-Herrera J; Daneluzzi D; Gangadharam PR
    Tuber Lung Dis; 1996 Apr; 77(2):154-9. PubMed ID: 8762850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of benzoxazinorifamycin KRM-1648 on cytokine production at sites of Mycobacterium avium complex infection induced in mice.
    Tomioka H; Sato K; Shimizu T; Sano C; Akaki T; Saito H; Fujii K; Hidaka T
    Antimicrob Agents Chemother; 1997 Feb; 41(2):357-62. PubMed ID: 9021192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with glycyrrhizin against Mycobacterium avium complex infection in mice].
    Shimizu T; Tomioka H; Sato K; Akaki T; Ogasawara K; Kawahara S
    Kekkaku; 1999 Aug; 74(8):617-21. PubMed ID: 10487030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemoprophylaxis against Mycobacterium avium complex infection induced in mice].
    Saito H; Murakami K; Kobayashi K; Gidoh M; Hidaka T; Kwon HH
    Kekkaku; 1999 Sep; 74(9):677-81. PubMed ID: 10535281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Profiles of expression of the therapeutic efficacy of KRM-1648 in mice infected with Mycobacterium avium complex at different challenge doses].
    Shimizu T; Ogasawara K; Sato K; Sano C; Tomioka H
    Kekkaku; 2001 May; 76(5):413-8. PubMed ID: 11449696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages.
    Sato K; Akaki T; Tomioka H
    J Antimicrob Chemother; 1998 Jan; 41(1):77-83. PubMed ID: 9511040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis.
    Hirata T; Saito H; Tomioka H; Sato K; Jidoi J; Hosoe K; Hidaka T
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2295-303. PubMed ID: 8619585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice.
    Yamamoto T; Amitani R; Suzuki K; Tanaka E; Murayama T; Kuze F
    Antimicrob Agents Chemother; 1996 Feb; 40(2):429-32. PubMed ID: 8834892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.